Payment overview · 2025
General Payments
$466.33
8 reported records · 4 companies
Healthcare provider profile · identity verified
Arshad Anwar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1174635916
Verified facts
What the public records show
CMS Open Payments records show Arshad Anwar, MD received $466.33 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 60.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $281.37 | 60.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $111.07 | 23.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.98 | 10.3% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.91 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $466.33 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $249.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $111.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $111.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
105 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
61 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1125 | 270 |
| Amlodipine Besylate | Amlodipine Besylate | 796 | 195 |
| Gabapentin | Gabapentin | 665 | 143 |
| Tamsulosin Hcl | Tamsulosin Hcl | 614 | 148 |
| Omeprazole | Omeprazole | 612 | 138 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 584 | 192 |
| Losartan Potassium | Losartan Potassium | 495 | 120 |
| Jardiance | Empagliflozin | 456 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 452 | 129 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 452 | 103 |
| Metformin Hcl | Metformin Hcl | 425 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 423 | 109 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 406 | 103 |
| Simvastatin | Simvastatin | 388 | 100 |
| Farxiga | Dapagliflozin Propanediol | 378 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 77 |
| Vascepa | Icosapent Ethyl | 347 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 346 | 77 |
| Lisinopril | Lisinopril | 346 | 87 |
| Glipizide | Glipizide | 340 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 79 |
| Montelukast Sodium | Montelukast Sodium | 300 | 67 |
| Famotidine | Famotidine | 274 | 77 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 267 | 69 |
| Metformin Hcl Er | Metformin Hcl | 223 | 46 |
| Enalapril Maleate | Enalapril Maleate | 216 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 51 |
| Ammonium Lactate | Ammonium Lactate | 196 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 41 |
| Finasteride | Finasteride | 174 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 34 |
| Carvedilol | Carvedilol | 171 | 35 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 166 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 35 |
| Ozempic | Semaglutide | 151 | 33 |
| Alendronate Sodium | Alendronate Sodium | 149 | 34 |
| Atenolol | Atenolol | 148 | 32 |
| Glipizide Er | Glipizide | 147 | 40 |
| Donepezil Hcl | Donepezil Hcl | 145 | 29 |
| Lactulose | Lactulose | 145 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 139 | 39 |
| Clotrimazole | Clotrimazole | 139 | 47 |
| Furosemide | Furosemide | 139 | 34 |
| Allopurinol | Allopurinol | 130 | 25 |
| Trulicity | Dulaglutide | 130 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 123 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 56 |
| Glimepiride | Glimepiride | 117 | 27 |
| Januvia | Sitagliptin Phosphate | 115 | 32 |
| Linzess | Linaclotide | 105 | 26 |
| Jentadueto | Linagliptin/Metformin Hcl | 100 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 100 | 21 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 96 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 14 |
| Meloxicam | Meloxicam | 89 | 65 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 15 |
| Eliquis | Apixaban | 85 | 19 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 85 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 17 |
| Ezetimibe | Ezetimibe | 81 | 23 |
| Repaglinide | Repaglinide | 81 | 18 |
| Tradjenta | Linagliptin | 75 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 18 |
| Brilinta | Ticagrelor | 69 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 69 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 16 |
| Creon | Lipase/Protease/Amylase | 63 | 13 |
| Mounjaro | Tirzepatide | 63 | 13 |
| Novolog Flexpen | Insulin Aspart | 62 | 14 |
| Potassium Chloride | Potassium Chloride | 62 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 51 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | suppressed |
| Fenofibrate | Fenofibrate | 57 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 12 |
| Trazodone Hcl | Trazodone Hcl | 54 | 12 |
| Rybelsus | Semaglutide | 53 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 12 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 11 |
| Ramipril | Ramipril | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 41 |
| Meclizine Hcl | Meclizine Hcl | 49 | 16 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 33 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Spironolactone | Spironolactone | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 42 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 45 | 15 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 44 | 18 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 43 | 18 |
| Labetalol Hcl | Labetalol Hcl | 43 | 11 |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | 18 |
| Metformin Er Gastric | Metformin Hcl | 38 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | 16 |
| Hydrocortisone | Hydrocortisone | 37 | 13 |
| Imipramine Hcl | Imipramine Hcl | 37 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 36 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 35 | 18 |
| Ketoconazole | Ketoconazole | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Procto-Med Hc | Hydrocortisone | 33 | 11 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Calcitriol | Calcitriol | 31 | suppressed |
| Fluocinonide | Fluocinonide | 31 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 26 |
| Veltassa | Patiromer Calcium Sorbitex | 29 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 27 | 12 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 27 | suppressed |
| Viread | Tenofovir Disoproxil Fumarate | 27 | suppressed |
| Acetic Acid | Acetic Acid | 26 | 16 |
| Folic Acid | Folic Acid | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | 19 |
| Methimazole | Methimazole | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 16 |
| Prednisone | Prednisone | 22 | 15 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 22 | suppressed |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Cialis | Tadalafil | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Rayos | Prednisone | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $466.33 · 8 records | GlaxoSmithKline, LLC. | ACCRUFER, NUCALA, Ozempic, QULIPTA, TRELEGY ELLIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error